Table A8.
Parameter values varied in deterministic sensitivity analyses.
| Parameter | Original Value | Lower Limit | Upper Limit |
|---|---|---|---|
| Patient Characteristics | |||
| Bodyweight | 81.8000 | 77.9723 | 85.6277 |
| BSA | 1.9780 | 1.9251 | 2.0309 |
| Resource Use | |||
| Pre-Progression Resource Use: Full blood count | 0.3333 | 0.2157 | 0.4761 |
| Pre-Progression Resource Use: X-ray | 0.1667 | 0.1079 | 0.2381 |
| Pre-Progression Resource Use: Blood glucose | 0.3333 | 0.2157 | 0.4761 |
| Pre-Progression Resource Use: Lactate dehydrogenase | 0.3333 | 0.2157 | 0.4761 |
| Pre-Progression Resource Use: CT Scan | 0.1667 | 0.1079 | 0.2381 |
| Pre-Progression Resource Use: Office visit | 0.1667 | 0.1079 | 0.2381 |
| Pre-Progression Cured: Resource Use: Office visit | 0.1667 | 0.1079 | 0.2381 |
| Post-Progression Resource Use: Full blood count | 1.0000 | 0.6471 | 1.4284 |
| Post-Progression Resource Use: X-ray | 0.3333 | 0.2157 | 0.4761 |
| Post-Progression Resource Use: Blood glucose | 1.0000 | 0.6471 | 1.4284 |
| Post-Progression Resource Use: Lactate dehydrogenase | 1.0000 | 0.6471 | 1.4284 |
| Post-Progression Resource Use: Office visit | 1.0000 | 0.6471 | 1.4284 |
| Post-Progression Resource Use: CT Scan | 0.3333 | 0.2157 | 0.4761 |
| Post-Progression Resource Use: Hospitalization | 0.0833 | 0.0539 | 0.1190 |
| End-of-life Resource Use: Palliative care (one-off) | 1.0000 | 0.6471 | 1.4284 |
| Brexucabtagene autoleucel—Proportion ICU Stay | 0.2200 | 0.1402 | 0.3119 |
| Brexucabtagene autoleucel—Proportion Non-ICU—Hospital days | 16.5000 | −4.5696 | 37.5696 |
| Bridging Therapy Proportion | 0.3676 | 0.3133 | 0.4237 |
| Cost: Initial Hospitalization: Intensive Care Unit Day | CAD 8,343.7300 | CAD 5399.6221 | 1 CAD 1918.2165 |
| Cost: Initial Hospitalization: Inpatient Day (Non-ICU) | CAD 1580.5300 | CAD 1022.8357 | CAD 2257.6352 |
| Cost: Stem cell transplant | CAD 166,855.5300 | CAD 10,7980.1014 | CAD 23,8337.0904 |
| Cost: Office visit | CAD 174.6400 | CAD 113.0178 | CAD 249.4565 |
| Cost: Palliative care (one-off) | CAD 35,262.4800 | CAD 22,820.0178 | CAD 50,369.0641 |
| Cost: Full blood count | CAD 4.1200 | CAD 2.6662 | CAD 5.8850 |
| Cost: X-ray | CAD 23.1500 | CAD 14.9815 | CAD 33.0676 |
| Cost: Blood glucose | CAD 1.3300 | CAD 0.8607 | CAD 1.8998 |
| Cost: Lactate dehydrogenase | CAD 1.3300 | CAD 0.8607 | CAD 1.8998 |
| Cost: Inpatient stay | CAD 1580.5300 | CAD 1022.8357 | CAD 2257.6352 |
| Cost: CT Scan | CAD 195.0000 | CAD 126.1937 | CAD 278.5388 |
| Cost: Hospitalization | CAD 13,215.8400 | CAD 8552.5948 | CAD 18,877.5574 |
| Utility | |||
| Utility: Pre-progression (up to 60 months) | 0.7800 | 0.7601 | 0.7993 |
| Utility: Pre-progression, cured (beyond 60 months) | 0.7852 | 0.7653 | 0.8045 |
| Utility: Post-progression | 0.6800 | 0.6321 | 0.7261 |
| Adverse Events | |||
| Brexucabtagene autoleucel AE incidence: Hypotension | 0.2206 | 0.1305 | 0.3265 |
| Brexucabtagene autoleucel AE incidence: Neutrophil count decreased | 0.5294 | 0.4103 | 0.6468 |
| Brexucabtagene autoleucel AE incidence: White blood cell count decreased | 0.4118 | 0.2977 | 0.5308 |
| Brexucabtagene autoleucel AE incidence: Hypoxia | 0.2059 | 0.1186 | 0.3097 |
| Brexucabtagene autoleucel AE incidence: Hypophosphataemia | 0.2206 | 0.1305 | 0.3265 |
| Brexucabtagene autoleucel AE incidence: Neutropenia | 0.3382 | 0.2308 | 0.4548 |
| Brexucabtagene autoleucel AE incidence: Hyponatraemia | 0.1029 | 0.0427 | 0.1855 |
| Brexucabtagene autoleucel AE incidence: Alanine aminotransferase increased | 0.0882 | 0.0333 | 0.1663 |
| Brexucabtagene autoleucel AE incidence: Encephalopathy | 0.1765 | 0.0956 | 0.2756 |
| Brexucabtagene autoleucel AE incidence: Hypokalaemia | 0.1471 | 0.0735 | 0.2405 |
| Brexucabtagene autoleucel AE incidence: Hypocalcaemia | 0.0882 | 0.0333 | 0.1663 |
| Brexucabtagene autoleucel AE incidence: Thrombocytopenia | 0.1618 | 0.0844 | 0.2582 |
| Brexucabtagene autoleucel AE incidence: Aspartate aminotransferase increased | 0.1029 | 0.0427 | 0.1855 |
| Brexucabtagene autoleucel AE incidence: Confusional state | 0.1176 | 0.0526 | 0.2042 |
| Brexucabtagene autoleucel AE incidence: Hypertension | 0.1324 | 0.0629 | 0.2225 |
| Brexucabtagene autoleucel AE incidence: Acute Kidney Injury | 0.0735 | 0.0244 | 0.1465 |
| Brexucabtagene autoleucel AE incidence: Leukopenia | 0.1471 | 0.0735 | 0.2405 |
| Brexucabtagene autoleucel AE incidence: Lymphocyte count decreased | 0.0882 | 0.0333 | 0.1663 |
| Brexucabtagene autoleucel AE incidence: Pneumonia | 0.1324 | 0.0629 | 0.2225 |
| Brexucabtagene autoleucel AE incidence: Respiratory Failure | 0.0588 | 0.0163 | 0.1259 |
| Brexucabtagene autoleucel AE incidence: Sepsis | 0.0588 | 0.0163 | 0.1259 |
| Disutility Cytokine release syndrome | 0.7800 | 0.4087 | 0.9850 |
| Disutility Pyrexia | 0.1100 | 0.0707 | 0.1566 |
| Disutility Anaemia | 0.1200 | 0.0771 | 0.1708 |
| Disutility Platelet Count decreased | 0.1100 | 0.0707 | 0.1566 |
| Disutility Hypotension | 0.1500 | 0.0961 | 0.2133 |
| Disutility Neutrophil count decreased | 0.1500 | 0.0961 | 0.2133 |
| Disutility White blood cell count decreased | 0.1500 | 0.0961 | 0.2133 |
| Disutility Hypoxia | 0.1100 | 0.0707 | 0.1566 |
| Disutility Hypophosphataemia | 0.1500 | 0.0961 | 0.2133 |
| Disutility Neutropenia | 0.0900 | 0.0579 | 0.1282 |
| Disutility Hyponatraemia | 0.1500 | 0.0961 | 0.2133 |
| Disutility Alanine aminotransferase increased | 0.1500 | 0.0961 | 0.2133 |
| Disutility Encephalopathy | 0.1500 | 0.0961 | 0.2133 |
| Disutility Hypokalaemia | 0.1500 | 0.0961 | 0.2133 |
| Disutility Hypocalcaemia | 0.1500 | 0.0961 | 0.2133 |
| Disutility Thrombocytopenia | 0.1100 | 0.0707 | 0.1566 |
| Disutility Aspartate aminotransferase increased | 0.1500 | 0.0961 | 0.2133 |
| Disutility Confusional state | 0.1500 | 0.0961 | 0.2133 |
| Disutility Hypertension | 0.1500 | 0.0961 | 0.2133 |
| Disutility Acute Kidney Injury | 0.1500 | 0.0961 | 0.2133 |
| Disutility Leukopenia | 0.1500 | 0.0961 | 0.2133 |
| Disutility Lymphocyte count decreased | 0.1500 | 0.0961 | 0.2133 |
| Disutility Pneumonia | 0.1500 | 0.0961 | 0.2133 |
| Disutility Respiratory Failure | 0.1500 | 0.0961 | 0.2133 |
| Disutility Sepsis | 0.1500 | 0.0961 | 0.2133 |
| Duration Cytokine release syndrome | 4.0000 | 2.5886 | 5.7136 |
| Duration Pyrexia | 2.0000 | 1.2943 | 2.8568 |
| Duration Anaemia | 14.0000 | 9.0601 | 19.9977 |
| Duration Platelet Count decreased | 50.0000 | 32.3574 | 71.4202 |
| Duration Hypotension | 5.0000 | 3.2357 | 7.1420 |
| Duration Neutrophil count decreased | 17.0000 | 11.0015 | 24.2829 |
| Duration White blood cell count decreased | 40.0000 | 25.8859 | 57.1362 |
| Duration Hypoxia | 2.0000 | 1.2943 | 2.8568 |
| Duration Hypophosphataemia | 5.0000 | 3.2357 | 7.1420 |
| Duration Neutropenia | 47.0000 | 30.4159 | 67.1350 |
| Duration Hyponatraemia | 7.0000 | 4.5300 | 9.9988 |
| Duration Alanine aminotransferase increased | 7.0000 | 4.5300 | 9.9988 |
| Duration Encephalopathy | 9.0000 | 5.8243 | 12.8556 |
| Duration Hypokalaemia | 7.0000 | 4.5300 | 9.9988 |
| Duration Hypocalcaemia | 7.0000 | 4.5300 | 9.9988 |
| Duration Thrombocytopenia | 63.0000 | 40.7703 | 89.9894 |
| Duration Aspartate aminotransferase increased | 7.0000 | 4.5300 | 9.9988 |
| Duration Confusional state | 7.0000 | 4.5300 | 9.9988 |
| Duration Hypertension | 5.0000 | 3.2357 | 7.1420 |
| Duration Acute Kidney Injury | 7.0000 | 4.5300 | 9.9988 |
| Duration Leukopenia | 21.0000 | 13.5901 | 29.9965 |
| Duration Lymphocyte count decreased | 64.0000 | 41.4174 | 91.4178 |
| Duration Pneumonia | 7.0000 | 4.5300 | 9.9988 |
| Duration Respiratory Failure | 7.0000 | 4.5300 | 9.9988 |
| Duration Sepsis | 7.0000 | 4.5300 | 9.9988 |
| AE cost: Cytokine release syndrome | CAD 18,366.9647 | CAD 11,886.1311 | CAD 26,235.4440 |
Abbreviations: BSA = body surface area; AE = adverse events; ICU intensive care unit.